Sichenzia Ross Friedman Ference LLP Represents Viatar CTC Solutions Inc. in a $4.2 Million Private Placement

Press Release – New York, NY – March 3, 2016 – Nationally recognized securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that it has represented Viatar CTC Solutions Inc., a medical technology company focused on the treatment of patients with metastatic cancer, in a private placement of $4.2 million of Series B Preferred Stock.

In connection with the offering, the Company sold approximately 1.7 million shares of Series B Preferred Stock for an aggregate purchase price of approximately $4.2 million (including shares of a private company valued at approximately $3.7 million and cash of $500,000). The Sichenzia Ross Friedman Ference LLP team was led by Partners Gregory Sichenzia and Darrin Ocasio and associate Jeff Cahlon.

• About
• Latest Posts

Sichenzia Ross Ference LLP

Sichenzia Ross Ference LLP is a nationally recognized securities and corporate law firm that provides experienced representation in all matters involving the securities industry. Super Lawyers consistently recognizes our attorneys as among the highest rated securities lawyers in the nation. Our attorneys specialize in advising clients on private placements, initial (IPOs) and secondary public offerings, alternative public offerings, preparation of SEC filings and listings on major capital stock exchanges such as the NYSE (New York Stock Exchange), NASDAQ and OTC markets. In addition, our litigation and arbitration attorneys are highly skilled in representing clients from routine lawsuits to complex cases before the SEC, FINRA and other tribunals. We also represent clients in a range of residential and commercial real estate and trusts and estates matters.

Visit SRF's LinkedIn page

Latest posts by Sichenzia Ross Ference LLP (see all)

• Sichenzia Ross Ference LLP Represents Quest Solutions, Inc. in $5 Million Private Placement - April 10, 2019
• Sichenzia Ross Ference LLP Congratulates INmune Bio Inc., on Initial Public Offering - April 10, 2019
• FDA sets first hearing on CBD in May as the agency looks at legalizing the cannabis compound in food and drinks - April 4, 2019